Published in Br J Pharmacol on December 18, 2006
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Chemical probes of endocannabinoid metabolism. Pharmacol Rev (2013) 1.68
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol (2007) 1.39
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol (2007) 1.18
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci (2012) 1.04
Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res (2010) 1.04
Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 1.01
Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol (2009) 1.01
Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res (2011) 0.97
The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol (2009) 0.94
Inhibitors of monoacylglycerol lipase as novel analgesics. Br J Pharmacol (2007) 0.93
Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain (2009) 0.93
Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One (2010) 0.91
Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol (2008) 0.86
A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity. Bioorg Med Chem Lett (2008) 0.78
Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. J Neurophysiol (2014) 0.76
The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief. ISRN Anesthesiol (2011) 0.76
The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain. Neuroscience (2013) 0.75
Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase. J Neural Transm (Vienna) (2014) 0.75
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol (1978) 13.02
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
The formalin test: an evaluation of the method. Pain (1992) 7.29
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 2.43
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain (1996) 2.20
Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett (1998) 2.16
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther (2002) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res (1990) 1.82
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem (2005) 1.78
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci (2000) 1.55
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol (2000) 1.50
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci (1997) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience (1999) 1.37
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol (2004) 1.34
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience (2005) 1.30
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids (2002) 1.29
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J (1998) 1.23
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.23
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids (2002) 1.17
Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci (2004) 1.14
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun (1996) 1.10
Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain (2006) 1.09
Formalin induces biphasic activity in C-fibers in the rat. Neurosci Lett (1996) 1.07
Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther (1995) 1.06
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol (2000) 1.06
Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci (2000) 1.01
Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res (2006) 1.00
Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology (2006) 0.99
Second phase of formalin-induced excitation of spinal dorsal horn neurons in spinalized rats is reversed by sciatic nerve block. Eur J Neurosci (2002) 0.96
Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol (2006) 0.96
Optimal scoring strategies and weights for the formalin test in rats. Pain (1997) 0.91
Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. J Med Chem (1999) 0.77
A new mechanical method for measuring rat paw edema. Pharmacology (1978) 0.77
Efficacy of epidural blood patch in the obstetric population. Int J Obstet Anesth (1999) 2.42
Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth (1992) 1.99
[Isotretinoin in danger! So are the dermatologists!]. Ann Dermatol Venereol (2005) 1.40
Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience (2005) 1.30
A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature (1994) 1.17
Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact (2009) 1.12
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure (1995) 1.10
Antinociceptive effects of tetrodotoxin (TTX) in rodents. Br J Anaesth (2006) 1.04
Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 1.01
Descriptive study to compare patient recall of information: nurse-taught versus video supplement. Can Oncol Nurs J (1999) 0.98
Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse (1989) 0.97
Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase R1 subunit. J Biol Chem (1994) 0.94
Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag (2005) 0.90
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents. J Med Chem (1995) 0.84
Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Nouv Rev Fr Hematol (1995) 0.83
French teenagers and artificial tanning. J Eur Acad Dermatol Venereol (2012) 0.83
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J Med Chem (1996) 0.83
Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives. J Med Chem (1993) 0.82
Phonomyography of the corrugator supercilii muscle: signal characteristics, best recording site and comparison with acceleromyography. Br J Anaesth (2002) 0.79
Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth (1993) 0.78
Bombesin modulates the association of Src with a nuclear 110-kd protein expressed in dividing prostate cells. J Androl (2000) 0.78
NMR imaging in temporal lobe epilepsy due to gliomas. J Comput Assist Tomogr (1984) 0.78
Anaesthetic management of a 2.900 kg neonate with a C3-C4 dislocation. Paediatr Anaesth (1995) 0.77
Clinical use of a nonferromagnetic needle for magnetic resonance-guided biopsy. Gastrointest Radiol (1989) 0.77
[Breast cancer disclosed by palmar fasciitis]. Rev Med Interne (1996) 0.75
Efficiency of epidural blood patches in the obstetrics. Can J Anaesth (1998) 0.75
The patient's viewpoint on TMJ implants. J Oral Maxillofac Surg (1991) 0.75
Age and opioid patient-controlled analgesia use. Anaesthesia (1998) 0.75
[Reduction of nose fracture: laryngeal mask or tracheal intubation?]. Ann Fr Anesth Reanim (1992) 0.75
Experimental pre-emptive analgesia: what value for the clinician? Can J Anaesth (2001) 0.75
Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. J Eur Acad Dermatol Venereol (2014) 0.75
[Interactions between the opioid and cannabinoid systems]. Ann Fr Anesth Reanim (2000) 0.75
Analgesic interaction between ondansetron and acetaminophen after tonsillectomy in children: the Paratron randomized, controlled trial. Eur J Pain (2014) 0.75
Airway obstruction during anaesthesia for anterior cervical cord decompression. Can J Anaesth (1994) 0.75
[The impact of rosacea on patients' daily life: a transverse observational study among private dermatologists]. Ann Dermatol Venereol (2012) 0.75
Ureido-based peptidomimetic inhibitor of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation. J Med Chem (1996) 0.75
Contrast induced myocardial signal reduction: effect of lanthanide chelates on ultra high speed MR images. Magn Reson Imaging (1994) 0.75
[Socio-demographic study of privately practicing dermatologists in metropolitan France in 2011]. Ann Dermatol Venereol (2012) 0.75
[A case for diagnosis: Pseudomonas aeruginosa intertrigo]. Ann Dermatol Venereol (1992) 0.75
[Incontinentia pigmenti]. Arch Pediatr (1996) 0.75
[What is your diagnosis? Captopril-induced pemphigus]. Ann Dermatol Venereol (1991) 0.75
[Foreign body granuloma on calcified loa loa filariasis]. Ann Dermatol Venereol (1992) 0.75
[Treatment of hyperhidrosis by botulinum toxin]. Ann Dermatol Venereol (1999) 0.75
Intravenous administration of paracetamol (propacetamol) for postoperative analgesia. Anaesthesia (1994) 0.75
[Guidelines for the good use of isotretinoin in private practice: a prospective observational study of 1263 acne patients]. Ann Dermatol Venereol (2009) 0.75
[Anal fissures: treatment with botulinum toxin]. Ann Dermatol Venereol (2000) 0.75
[Angular cheilitis: how do you manage?]. Ann Dermatol Venereol (2001) 0.75
[Key aspects of excessive hair in 2005]. Ann Dermatol Venereol (2005) 0.75
[Leprosy. Developmental modalities]. Rev Prat (1992) 0.75
[Asthma: a disease of the future]. Rev Med Interne (1994) 0.75